PMID- 28835401
OWN - NLM
STAT- MEDLINE
DCOM- 20170915
LR  - 20220316
IS  - 1526-632X (Electronic)
IS  - 0028-3878 (Print)
IS  - 0028-3878 (Linking)
VI  - 89
IP  - 11
DP  - 2017 Sep 12
TI  - Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of 
      continuous MS therapy.
PG  - 1107-1116
LID - 10.1212/WNL.0000000000004313 [doi]
AB  - OBJECTIVE: To evaluate 5-year efficacy and safety of alemtuzumab in 
      treatment-naive patients with active relapsing-remitting MS (RRMS) (CARE-MS I; 
      NCT00530348). METHODS: Alemtuzumab-treated patients received treatment courses at 
      baseline and 12 months later; after the core study, they could enter an extension 
      (NCT00930553) with as-needed alemtuzumab retreatment for relapse or MRI activity. 
      Assessments included annualized relapse rate (ARR), 6-month confirmed disability 
      worsening (CDW; >/=1-point Expanded Disability Status Scale [EDSS] score increase 
      [>/=1.5 if baseline EDSS = 0]), 6-month confirmed disability improvement (CDI; 
      >/=1-point EDSS decrease [baseline score >/=2.0]), no evidence of disease activity 
      (NEDA), brain volume loss (BVL), and adverse events (AEs). RESULTS: Most 
      alemtuzumab-treated patients (95.1%) completing CARE-MS I enrolled in the 
      extension; 68.5% received no additional alemtuzumab treatment. ARR remained low 
      in years 3, 4, and 5 (0.19, 0.14, and 0.15). Over years 0-5, 79.7% were free of 
      6-month CDW; 33.4% achieved 6-month CDI. Most patients (61.7%, 60.2%, and 62.4%) 
      had NEDA in years 3, 4, and 5. Median yearly BVL improved over years 2-4, 
      remaining low in year 5 (years 1-5: -0.59%, -0.25%, -0.19%, -0.15%, and -0.20%). 
      Exposure-adjusted incidence rates of most AEs declined in the extension relative 
      to the core study. Thyroid disorder incidences peaked at year 3 and subsequently 
      declined. CONCLUSIONS: Based on these data, alemtuzumab provides durable efficacy 
      through 5 years in the absence of continuous treatment, with most patients not 
      receiving additional courses. CLINICALTRIALSGOV IDENTIFIER: NCT00530348; 
      NCT00930553. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence 
      that alemtuzumab durably improves efficacy outcomes and slows BVL in patients 
      with RRMS.
CI  - Copyright (c) 2017 The Author(s). Published by Wolters Kluwer Health, Inc. on 
      behalf of the American Academy of Neurology.
FAU - Havrdova, Eva
AU  - Havrdova E
AD  - From the Department of Neurology and Center for Clinical Neuroscience (E.H.), 
      First Faculty of Medicine, Charles University and General University Hospital in 
      Prague, Czech Republic; NeuroRx Research (D.L.A.), Montreal; Department of 
      Neurology and Neurosurgery (D.L.A.), Montreal Neurological Institute, McGill 
      University, Quebec, Canada; Mellen Center (J.A.C.), Cleveland Clinic, OH; 
      Department of Neurology and Center for Neuropsychiatry (H.-P.H.), Medical 
      Faculty, Heinrich-Heine University, Dusseldorf, Germany; MS Clinic of Central 
      Texas (E.J.F.), Central Texas Neurology Consultants, Round Rock; Queen Mary 
      University of London (G.G.), Barts and The London School of Medicine, UK; 
      Neuroimmunology and Multiple Sclerosis Research (S.S.), Department of Neurology, 
      University Hospital Zurich and University of Zurich, Switzerland; Department of 
      Neurology (K.W.S.), Medical University of Lodz, Poland; The University of British 
      Columbia (A.T.), Vancouver, Canada; Department of Clinical Neurosciences 
      (D.A.S.C., A.J.C.), University of Cambridge, UK; Sanofi (D.H.M., K.T., C.E.R., 
      D.J., M.A.P.), Cambridge, MA; Evidence Scientific Solutions (R.J.H.), Sydney, 
      NSW, Australia; and Evidence Scientific Solutions (P.X.), Philadelphia, PA. 
      M.A.P. is currently affiliated with Wave Life Sciences, Cambridge, MA. 
      eva.havrdova@lf1.cuni.cz.
FAU - Arnold, Douglas L
AU  - Arnold DL
AD  - From the Department of Neurology and Center for Clinical Neuroscience (E.H.), 
      First Faculty of Medicine, Charles University and General University Hospital in 
      Prague, Czech Republic; NeuroRx Research (D.L.A.), Montreal; Department of 
      Neurology and Neurosurgery (D.L.A.), Montreal Neurological Institute, McGill 
      University, Quebec, Canada; Mellen Center (J.A.C.), Cleveland Clinic, OH; 
      Department of Neurology and Center for Neuropsychiatry (H.-P.H.), Medical 
      Faculty, Heinrich-Heine University, Dusseldorf, Germany; MS Clinic of Central 
      Texas (E.J.F.), Central Texas Neurology Consultants, Round Rock; Queen Mary 
      University of London (G.G.), Barts and The London School of Medicine, UK; 
      Neuroimmunology and Multiple Sclerosis Research (S.S.), Department of Neurology, 
      University Hospital Zurich and University of Zurich, Switzerland; Department of 
      Neurology (K.W.S.), Medical University of Lodz, Poland; The University of British 
      Columbia (A.T.), Vancouver, Canada; Department of Clinical Neurosciences 
      (D.A.S.C., A.J.C.), University of Cambridge, UK; Sanofi (D.H.M., K.T., C.E.R., 
      D.J., M.A.P.), Cambridge, MA; Evidence Scientific Solutions (R.J.H.), Sydney, 
      NSW, Australia; and Evidence Scientific Solutions (P.X.), Philadelphia, PA. 
      M.A.P. is currently affiliated with Wave Life Sciences, Cambridge, MA.
FAU - Cohen, Jeffrey A
AU  - Cohen JA
AD  - From the Department of Neurology and Center for Clinical Neuroscience (E.H.), 
      First Faculty of Medicine, Charles University and General University Hospital in 
      Prague, Czech Republic; NeuroRx Research (D.L.A.), Montreal; Department of 
      Neurology and Neurosurgery (D.L.A.), Montreal Neurological Institute, McGill 
      University, Quebec, Canada; Mellen Center (J.A.C.), Cleveland Clinic, OH; 
      Department of Neurology and Center for Neuropsychiatry (H.-P.H.), Medical 
      Faculty, Heinrich-Heine University, Dusseldorf, Germany; MS Clinic of Central 
      Texas (E.J.F.), Central Texas Neurology Consultants, Round Rock; Queen Mary 
      University of London (G.G.), Barts and The London School of Medicine, UK; 
      Neuroimmunology and Multiple Sclerosis Research (S.S.), Department of Neurology, 
      University Hospital Zurich and University of Zurich, Switzerland; Department of 
      Neurology (K.W.S.), Medical University of Lodz, Poland; The University of British 
      Columbia (A.T.), Vancouver, Canada; Department of Clinical Neurosciences 
      (D.A.S.C., A.J.C.), University of Cambridge, UK; Sanofi (D.H.M., K.T., C.E.R., 
      D.J., M.A.P.), Cambridge, MA; Evidence Scientific Solutions (R.J.H.), Sydney, 
      NSW, Australia; and Evidence Scientific Solutions (P.X.), Philadelphia, PA. 
      M.A.P. is currently affiliated with Wave Life Sciences, Cambridge, MA.
FAU - Hartung, Hans-Peter
AU  - Hartung HP
AD  - From the Department of Neurology and Center for Clinical Neuroscience (E.H.), 
      First Faculty of Medicine, Charles University and General University Hospital in 
      Prague, Czech Republic; NeuroRx Research (D.L.A.), Montreal; Department of 
      Neurology and Neurosurgery (D.L.A.), Montreal Neurological Institute, McGill 
      University, Quebec, Canada; Mellen Center (J.A.C.), Cleveland Clinic, OH; 
      Department of Neurology and Center for Neuropsychiatry (H.-P.H.), Medical 
      Faculty, Heinrich-Heine University, Dusseldorf, Germany; MS Clinic of Central 
      Texas (E.J.F.), Central Texas Neurology Consultants, Round Rock; Queen Mary 
      University of London (G.G.), Barts and The London School of Medicine, UK; 
      Neuroimmunology and Multiple Sclerosis Research (S.S.), Department of Neurology, 
      University Hospital Zurich and University of Zurich, Switzerland; Department of 
      Neurology (K.W.S.), Medical University of Lodz, Poland; The University of British 
      Columbia (A.T.), Vancouver, Canada; Department of Clinical Neurosciences 
      (D.A.S.C., A.J.C.), University of Cambridge, UK; Sanofi (D.H.M., K.T., C.E.R., 
      D.J., M.A.P.), Cambridge, MA; Evidence Scientific Solutions (R.J.H.), Sydney, 
      NSW, Australia; and Evidence Scientific Solutions (P.X.), Philadelphia, PA. 
      M.A.P. is currently affiliated with Wave Life Sciences, Cambridge, MA.
FAU - Fox, Edward J
AU  - Fox EJ
AD  - From the Department of Neurology and Center for Clinical Neuroscience (E.H.), 
      First Faculty of Medicine, Charles University and General University Hospital in 
      Prague, Czech Republic; NeuroRx Research (D.L.A.), Montreal; Department of 
      Neurology and Neurosurgery (D.L.A.), Montreal Neurological Institute, McGill 
      University, Quebec, Canada; Mellen Center (J.A.C.), Cleveland Clinic, OH; 
      Department of Neurology and Center for Neuropsychiatry (H.-P.H.), Medical 
      Faculty, Heinrich-Heine University, Dusseldorf, Germany; MS Clinic of Central 
      Texas (E.J.F.), Central Texas Neurology Consultants, Round Rock; Queen Mary 
      University of London (G.G.), Barts and The London School of Medicine, UK; 
      Neuroimmunology and Multiple Sclerosis Research (S.S.), Department of Neurology, 
      University Hospital Zurich and University of Zurich, Switzerland; Department of 
      Neurology (K.W.S.), Medical University of Lodz, Poland; The University of British 
      Columbia (A.T.), Vancouver, Canada; Department of Clinical Neurosciences 
      (D.A.S.C., A.J.C.), University of Cambridge, UK; Sanofi (D.H.M., K.T., C.E.R., 
      D.J., M.A.P.), Cambridge, MA; Evidence Scientific Solutions (R.J.H.), Sydney, 
      NSW, Australia; and Evidence Scientific Solutions (P.X.), Philadelphia, PA. 
      M.A.P. is currently affiliated with Wave Life Sciences, Cambridge, MA.
FAU - Giovannoni, Gavin
AU  - Giovannoni G
AD  - From the Department of Neurology and Center for Clinical Neuroscience (E.H.), 
      First Faculty of Medicine, Charles University and General University Hospital in 
      Prague, Czech Republic; NeuroRx Research (D.L.A.), Montreal; Department of 
      Neurology and Neurosurgery (D.L.A.), Montreal Neurological Institute, McGill 
      University, Quebec, Canada; Mellen Center (J.A.C.), Cleveland Clinic, OH; 
      Department of Neurology and Center for Neuropsychiatry (H.-P.H.), Medical 
      Faculty, Heinrich-Heine University, Dusseldorf, Germany; MS Clinic of Central 
      Texas (E.J.F.), Central Texas Neurology Consultants, Round Rock; Queen Mary 
      University of London (G.G.), Barts and The London School of Medicine, UK; 
      Neuroimmunology and Multiple Sclerosis Research (S.S.), Department of Neurology, 
      University Hospital Zurich and University of Zurich, Switzerland; Department of 
      Neurology (K.W.S.), Medical University of Lodz, Poland; The University of British 
      Columbia (A.T.), Vancouver, Canada; Department of Clinical Neurosciences 
      (D.A.S.C., A.J.C.), University of Cambridge, UK; Sanofi (D.H.M., K.T., C.E.R., 
      D.J., M.A.P.), Cambridge, MA; Evidence Scientific Solutions (R.J.H.), Sydney, 
      NSW, Australia; and Evidence Scientific Solutions (P.X.), Philadelphia, PA. 
      M.A.P. is currently affiliated with Wave Life Sciences, Cambridge, MA.
FAU - Schippling, Sven
AU  - Schippling S
AD  - From the Department of Neurology and Center for Clinical Neuroscience (E.H.), 
      First Faculty of Medicine, Charles University and General University Hospital in 
      Prague, Czech Republic; NeuroRx Research (D.L.A.), Montreal; Department of 
      Neurology and Neurosurgery (D.L.A.), Montreal Neurological Institute, McGill 
      University, Quebec, Canada; Mellen Center (J.A.C.), Cleveland Clinic, OH; 
      Department of Neurology and Center for Neuropsychiatry (H.-P.H.), Medical 
      Faculty, Heinrich-Heine University, Dusseldorf, Germany; MS Clinic of Central 
      Texas (E.J.F.), Central Texas Neurology Consultants, Round Rock; Queen Mary 
      University of London (G.G.), Barts and The London School of Medicine, UK; 
      Neuroimmunology and Multiple Sclerosis Research (S.S.), Department of Neurology, 
      University Hospital Zurich and University of Zurich, Switzerland; Department of 
      Neurology (K.W.S.), Medical University of Lodz, Poland; The University of British 
      Columbia (A.T.), Vancouver, Canada; Department of Clinical Neurosciences 
      (D.A.S.C., A.J.C.), University of Cambridge, UK; Sanofi (D.H.M., K.T., C.E.R., 
      D.J., M.A.P.), Cambridge, MA; Evidence Scientific Solutions (R.J.H.), Sydney, 
      NSW, Australia; and Evidence Scientific Solutions (P.X.), Philadelphia, PA. 
      M.A.P. is currently affiliated with Wave Life Sciences, Cambridge, MA.
FAU - Selmaj, Krzysztof W
AU  - Selmaj KW
AD  - From the Department of Neurology and Center for Clinical Neuroscience (E.H.), 
      First Faculty of Medicine, Charles University and General University Hospital in 
      Prague, Czech Republic; NeuroRx Research (D.L.A.), Montreal; Department of 
      Neurology and Neurosurgery (D.L.A.), Montreal Neurological Institute, McGill 
      University, Quebec, Canada; Mellen Center (J.A.C.), Cleveland Clinic, OH; 
      Department of Neurology and Center for Neuropsychiatry (H.-P.H.), Medical 
      Faculty, Heinrich-Heine University, Dusseldorf, Germany; MS Clinic of Central 
      Texas (E.J.F.), Central Texas Neurology Consultants, Round Rock; Queen Mary 
      University of London (G.G.), Barts and The London School of Medicine, UK; 
      Neuroimmunology and Multiple Sclerosis Research (S.S.), Department of Neurology, 
      University Hospital Zurich and University of Zurich, Switzerland; Department of 
      Neurology (K.W.S.), Medical University of Lodz, Poland; The University of British 
      Columbia (A.T.), Vancouver, Canada; Department of Clinical Neurosciences 
      (D.A.S.C., A.J.C.), University of Cambridge, UK; Sanofi (D.H.M., K.T., C.E.R., 
      D.J., M.A.P.), Cambridge, MA; Evidence Scientific Solutions (R.J.H.), Sydney, 
      NSW, Australia; and Evidence Scientific Solutions (P.X.), Philadelphia, PA. 
      M.A.P. is currently affiliated with Wave Life Sciences, Cambridge, MA.
FAU - Traboulsee, Anthony
AU  - Traboulsee A
AD  - From the Department of Neurology and Center for Clinical Neuroscience (E.H.), 
      First Faculty of Medicine, Charles University and General University Hospital in 
      Prague, Czech Republic; NeuroRx Research (D.L.A.), Montreal; Department of 
      Neurology and Neurosurgery (D.L.A.), Montreal Neurological Institute, McGill 
      University, Quebec, Canada; Mellen Center (J.A.C.), Cleveland Clinic, OH; 
      Department of Neurology and Center for Neuropsychiatry (H.-P.H.), Medical 
      Faculty, Heinrich-Heine University, Dusseldorf, Germany; MS Clinic of Central 
      Texas (E.J.F.), Central Texas Neurology Consultants, Round Rock; Queen Mary 
      University of London (G.G.), Barts and The London School of Medicine, UK; 
      Neuroimmunology and Multiple Sclerosis Research (S.S.), Department of Neurology, 
      University Hospital Zurich and University of Zurich, Switzerland; Department of 
      Neurology (K.W.S.), Medical University of Lodz, Poland; The University of British 
      Columbia (A.T.), Vancouver, Canada; Department of Clinical Neurosciences 
      (D.A.S.C., A.J.C.), University of Cambridge, UK; Sanofi (D.H.M., K.T., C.E.R., 
      D.J., M.A.P.), Cambridge, MA; Evidence Scientific Solutions (R.J.H.), Sydney, 
      NSW, Australia; and Evidence Scientific Solutions (P.X.), Philadelphia, PA. 
      M.A.P. is currently affiliated with Wave Life Sciences, Cambridge, MA.
FAU - Compston, D Alastair S
AU  - Compston DAS
AD  - From the Department of Neurology and Center for Clinical Neuroscience (E.H.), 
      First Faculty of Medicine, Charles University and General University Hospital in 
      Prague, Czech Republic; NeuroRx Research (D.L.A.), Montreal; Department of 
      Neurology and Neurosurgery (D.L.A.), Montreal Neurological Institute, McGill 
      University, Quebec, Canada; Mellen Center (J.A.C.), Cleveland Clinic, OH; 
      Department of Neurology and Center for Neuropsychiatry (H.-P.H.), Medical 
      Faculty, Heinrich-Heine University, Dusseldorf, Germany; MS Clinic of Central 
      Texas (E.J.F.), Central Texas Neurology Consultants, Round Rock; Queen Mary 
      University of London (G.G.), Barts and The London School of Medicine, UK; 
      Neuroimmunology and Multiple Sclerosis Research (S.S.), Department of Neurology, 
      University Hospital Zurich and University of Zurich, Switzerland; Department of 
      Neurology (K.W.S.), Medical University of Lodz, Poland; The University of British 
      Columbia (A.T.), Vancouver, Canada; Department of Clinical Neurosciences 
      (D.A.S.C., A.J.C.), University of Cambridge, UK; Sanofi (D.H.M., K.T., C.E.R., 
      D.J., M.A.P.), Cambridge, MA; Evidence Scientific Solutions (R.J.H.), Sydney, 
      NSW, Australia; and Evidence Scientific Solutions (P.X.), Philadelphia, PA. 
      M.A.P. is currently affiliated with Wave Life Sciences, Cambridge, MA.
FAU - Margolin, David H
AU  - Margolin DH
AD  - From the Department of Neurology and Center for Clinical Neuroscience (E.H.), 
      First Faculty of Medicine, Charles University and General University Hospital in 
      Prague, Czech Republic; NeuroRx Research (D.L.A.), Montreal; Department of 
      Neurology and Neurosurgery (D.L.A.), Montreal Neurological Institute, McGill 
      University, Quebec, Canada; Mellen Center (J.A.C.), Cleveland Clinic, OH; 
      Department of Neurology and Center for Neuropsychiatry (H.-P.H.), Medical 
      Faculty, Heinrich-Heine University, Dusseldorf, Germany; MS Clinic of Central 
      Texas (E.J.F.), Central Texas Neurology Consultants, Round Rock; Queen Mary 
      University of London (G.G.), Barts and The London School of Medicine, UK; 
      Neuroimmunology and Multiple Sclerosis Research (S.S.), Department of Neurology, 
      University Hospital Zurich and University of Zurich, Switzerland; Department of 
      Neurology (K.W.S.), Medical University of Lodz, Poland; The University of British 
      Columbia (A.T.), Vancouver, Canada; Department of Clinical Neurosciences 
      (D.A.S.C., A.J.C.), University of Cambridge, UK; Sanofi (D.H.M., K.T., C.E.R., 
      D.J., M.A.P.), Cambridge, MA; Evidence Scientific Solutions (R.J.H.), Sydney, 
      NSW, Australia; and Evidence Scientific Solutions (P.X.), Philadelphia, PA. 
      M.A.P. is currently affiliated with Wave Life Sciences, Cambridge, MA.
FAU - Thangavelu, Karthinathan
AU  - Thangavelu K
AD  - From the Department of Neurology and Center for Clinical Neuroscience (E.H.), 
      First Faculty of Medicine, Charles University and General University Hospital in 
      Prague, Czech Republic; NeuroRx Research (D.L.A.), Montreal; Department of 
      Neurology and Neurosurgery (D.L.A.), Montreal Neurological Institute, McGill 
      University, Quebec, Canada; Mellen Center (J.A.C.), Cleveland Clinic, OH; 
      Department of Neurology and Center for Neuropsychiatry (H.-P.H.), Medical 
      Faculty, Heinrich-Heine University, Dusseldorf, Germany; MS Clinic of Central 
      Texas (E.J.F.), Central Texas Neurology Consultants, Round Rock; Queen Mary 
      University of London (G.G.), Barts and The London School of Medicine, UK; 
      Neuroimmunology and Multiple Sclerosis Research (S.S.), Department of Neurology, 
      University Hospital Zurich and University of Zurich, Switzerland; Department of 
      Neurology (K.W.S.), Medical University of Lodz, Poland; The University of British 
      Columbia (A.T.), Vancouver, Canada; Department of Clinical Neurosciences 
      (D.A.S.C., A.J.C.), University of Cambridge, UK; Sanofi (D.H.M., K.T., C.E.R., 
      D.J., M.A.P.), Cambridge, MA; Evidence Scientific Solutions (R.J.H.), Sydney, 
      NSW, Australia; and Evidence Scientific Solutions (P.X.), Philadelphia, PA. 
      M.A.P. is currently affiliated with Wave Life Sciences, Cambridge, MA.
FAU - Rodriguez, Claudio E
AU  - Rodriguez CE
AD  - From the Department of Neurology and Center for Clinical Neuroscience (E.H.), 
      First Faculty of Medicine, Charles University and General University Hospital in 
      Prague, Czech Republic; NeuroRx Research (D.L.A.), Montreal; Department of 
      Neurology and Neurosurgery (D.L.A.), Montreal Neurological Institute, McGill 
      University, Quebec, Canada; Mellen Center (J.A.C.), Cleveland Clinic, OH; 
      Department of Neurology and Center for Neuropsychiatry (H.-P.H.), Medical 
      Faculty, Heinrich-Heine University, Dusseldorf, Germany; MS Clinic of Central 
      Texas (E.J.F.), Central Texas Neurology Consultants, Round Rock; Queen Mary 
      University of London (G.G.), Barts and The London School of Medicine, UK; 
      Neuroimmunology and Multiple Sclerosis Research (S.S.), Department of Neurology, 
      University Hospital Zurich and University of Zurich, Switzerland; Department of 
      Neurology (K.W.S.), Medical University of Lodz, Poland; The University of British 
      Columbia (A.T.), Vancouver, Canada; Department of Clinical Neurosciences 
      (D.A.S.C., A.J.C.), University of Cambridge, UK; Sanofi (D.H.M., K.T., C.E.R., 
      D.J., M.A.P.), Cambridge, MA; Evidence Scientific Solutions (R.J.H.), Sydney, 
      NSW, Australia; and Evidence Scientific Solutions (P.X.), Philadelphia, PA. 
      M.A.P. is currently affiliated with Wave Life Sciences, Cambridge, MA.
FAU - Jody, Darlene
AU  - Jody D
AD  - From the Department of Neurology and Center for Clinical Neuroscience (E.H.), 
      First Faculty of Medicine, Charles University and General University Hospital in 
      Prague, Czech Republic; NeuroRx Research (D.L.A.), Montreal; Department of 
      Neurology and Neurosurgery (D.L.A.), Montreal Neurological Institute, McGill 
      University, Quebec, Canada; Mellen Center (J.A.C.), Cleveland Clinic, OH; 
      Department of Neurology and Center for Neuropsychiatry (H.-P.H.), Medical 
      Faculty, Heinrich-Heine University, Dusseldorf, Germany; MS Clinic of Central 
      Texas (E.J.F.), Central Texas Neurology Consultants, Round Rock; Queen Mary 
      University of London (G.G.), Barts and The London School of Medicine, UK; 
      Neuroimmunology and Multiple Sclerosis Research (S.S.), Department of Neurology, 
      University Hospital Zurich and University of Zurich, Switzerland; Department of 
      Neurology (K.W.S.), Medical University of Lodz, Poland; The University of British 
      Columbia (A.T.), Vancouver, Canada; Department of Clinical Neurosciences 
      (D.A.S.C., A.J.C.), University of Cambridge, UK; Sanofi (D.H.M., K.T., C.E.R., 
      D.J., M.A.P.), Cambridge, MA; Evidence Scientific Solutions (R.J.H.), Sydney, 
      NSW, Australia; and Evidence Scientific Solutions (P.X.), Philadelphia, PA. 
      M.A.P. is currently affiliated with Wave Life Sciences, Cambridge, MA.
FAU - Hogan, Richard J
AU  - Hogan RJ
AD  - From the Department of Neurology and Center for Clinical Neuroscience (E.H.), 
      First Faculty of Medicine, Charles University and General University Hospital in 
      Prague, Czech Republic; NeuroRx Research (D.L.A.), Montreal; Department of 
      Neurology and Neurosurgery (D.L.A.), Montreal Neurological Institute, McGill 
      University, Quebec, Canada; Mellen Center (J.A.C.), Cleveland Clinic, OH; 
      Department of Neurology and Center for Neuropsychiatry (H.-P.H.), Medical 
      Faculty, Heinrich-Heine University, Dusseldorf, Germany; MS Clinic of Central 
      Texas (E.J.F.), Central Texas Neurology Consultants, Round Rock; Queen Mary 
      University of London (G.G.), Barts and The London School of Medicine, UK; 
      Neuroimmunology and Multiple Sclerosis Research (S.S.), Department of Neurology, 
      University Hospital Zurich and University of Zurich, Switzerland; Department of 
      Neurology (K.W.S.), Medical University of Lodz, Poland; The University of British 
      Columbia (A.T.), Vancouver, Canada; Department of Clinical Neurosciences 
      (D.A.S.C., A.J.C.), University of Cambridge, UK; Sanofi (D.H.M., K.T., C.E.R., 
      D.J., M.A.P.), Cambridge, MA; Evidence Scientific Solutions (R.J.H.), Sydney, 
      NSW, Australia; and Evidence Scientific Solutions (P.X.), Philadelphia, PA. 
      M.A.P. is currently affiliated with Wave Life Sciences, Cambridge, MA.
FAU - Xenopoulos, Panos
AU  - Xenopoulos P
AD  - From the Department of Neurology and Center for Clinical Neuroscience (E.H.), 
      First Faculty of Medicine, Charles University and General University Hospital in 
      Prague, Czech Republic; NeuroRx Research (D.L.A.), Montreal; Department of 
      Neurology and Neurosurgery (D.L.A.), Montreal Neurological Institute, McGill 
      University, Quebec, Canada; Mellen Center (J.A.C.), Cleveland Clinic, OH; 
      Department of Neurology and Center for Neuropsychiatry (H.-P.H.), Medical 
      Faculty, Heinrich-Heine University, Dusseldorf, Germany; MS Clinic of Central 
      Texas (E.J.F.), Central Texas Neurology Consultants, Round Rock; Queen Mary 
      University of London (G.G.), Barts and The London School of Medicine, UK; 
      Neuroimmunology and Multiple Sclerosis Research (S.S.), Department of Neurology, 
      University Hospital Zurich and University of Zurich, Switzerland; Department of 
      Neurology (K.W.S.), Medical University of Lodz, Poland; The University of British 
      Columbia (A.T.), Vancouver, Canada; Department of Clinical Neurosciences 
      (D.A.S.C., A.J.C.), University of Cambridge, UK; Sanofi (D.H.M., K.T., C.E.R., 
      D.J., M.A.P.), Cambridge, MA; Evidence Scientific Solutions (R.J.H.), Sydney, 
      NSW, Australia; and Evidence Scientific Solutions (P.X.), Philadelphia, PA. 
      M.A.P. is currently affiliated with Wave Life Sciences, Cambridge, MA.
FAU - Panzara, Michael A
AU  - Panzara MA
AD  - From the Department of Neurology and Center for Clinical Neuroscience (E.H.), 
      First Faculty of Medicine, Charles University and General University Hospital in 
      Prague, Czech Republic; NeuroRx Research (D.L.A.), Montreal; Department of 
      Neurology and Neurosurgery (D.L.A.), Montreal Neurological Institute, McGill 
      University, Quebec, Canada; Mellen Center (J.A.C.), Cleveland Clinic, OH; 
      Department of Neurology and Center for Neuropsychiatry (H.-P.H.), Medical 
      Faculty, Heinrich-Heine University, Dusseldorf, Germany; MS Clinic of Central 
      Texas (E.J.F.), Central Texas Neurology Consultants, Round Rock; Queen Mary 
      University of London (G.G.), Barts and The London School of Medicine, UK; 
      Neuroimmunology and Multiple Sclerosis Research (S.S.), Department of Neurology, 
      University Hospital Zurich and University of Zurich, Switzerland; Department of 
      Neurology (K.W.S.), Medical University of Lodz, Poland; The University of British 
      Columbia (A.T.), Vancouver, Canada; Department of Clinical Neurosciences 
      (D.A.S.C., A.J.C.), University of Cambridge, UK; Sanofi (D.H.M., K.T., C.E.R., 
      D.J., M.A.P.), Cambridge, MA; Evidence Scientific Solutions (R.J.H.), Sydney, 
      NSW, Australia; and Evidence Scientific Solutions (P.X.), Philadelphia, PA. 
      M.A.P. is currently affiliated with Wave Life Sciences, Cambridge, MA.
FAU - Coles, Alasdair J
AU  - Coles AJ
CN  - CARE-MS I and CAMMS03409 Investigators
LA  - eng
SI  - ClinicalTrials.gov/NCT00530348
SI  - ClinicalTrials.gov/NCT00930553
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20170823
PL  - United States
TA  - Neurology
JT  - Neurology
JID - 0401060
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Immunologic Factors)
RN  - 3A189DH42V (Alemtuzumab)
SB  - IM
EIN - Neurology. 2018 Apr 17;90(16):755. PMID: 29661899
MH  - Alemtuzumab
MH  - Antibodies, Monoclonal, Humanized/adverse effects/*therapeutic use
MH  - Brain/diagnostic imaging/drug effects
MH  - Disability Evaluation
MH  - Follow-Up Studies
MH  - Humans
MH  - Immunologic Factors/adverse effects/*therapeutic use
MH  - Multiple Sclerosis, Relapsing-Remitting/diagnostic imaging/*drug therapy
MH  - Organ Size
MH  - Time Factors
MH  - Treatment Outcome
PMC - PMC5595278
EDAT- 2017/08/25 06:00
MHDA- 2017/09/16 06:00
PMCR- 2017/09/12
CRDT- 2017/08/25 06:00
PHST- 2016/08/09 00:00 [received]
PHST- 2017/02/23 00:00 [accepted]
PHST- 2017/08/25 06:00 [pubmed]
PHST- 2017/09/16 06:00 [medline]
PHST- 2017/08/25 06:00 [entrez]
PHST- 2017/09/12 00:00 [pmc-release]
AID - WNL.0000000000004313 [pii]
AID - NEUROLOGY2016762211 [pii]
AID - 10.1212/WNL.0000000000004313 [doi]
PST - ppublish
SO  - Neurology. 2017 Sep 12;89(11):1107-1116. doi: 10.1212/WNL.0000000000004313. Epub 
      2017 Aug 23.